drugset / Trial / NCT04310228
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
Timeline
- Start
- 2020-03-08
- Primary completion
- 2020-05
- Completion
- 2020-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Favipiravir | Small molecule | 600 mg | Oral |
| Comparator | Tocilizumab | Monoclonal antibody | 400 mg | Intravenous |